Efficacy of 0.18 mg Fluocinolone Acetonide Implant in NIU-Associated Macular Edema

Overview

This real-world study evaluated the clinical outcomes of a single 0.18 mg fluocinolone acetonide intravitreal implant (FAi) in 39 patients (50 eyes) with macular edema secondary to non-infectious uveitis (NIU). Over 12 months, significant improvements were observed in visual acuity and macular thickness, with a manageable safety profile.

Background

Macular edema is the leading cause of vision loss in uveitis patients, primarily due to inflammation disrupting the blood-retinal barrier. Non-infectious uveitis (NIU) accounts for the majority of posterior uveitis cases and is typically managed with systemic corticosteroids and immunomodulatory agents, which carry systemic side effects. Topical corticosteroids have limited efficacy in the posterior segment due to poor penetration. Sustained-release intravitreal corticosteroid implants, such as the fluocinolone acetonide implant (FAi), offer targeted therapy with prolonged drug delivery and reduced systemic exposure. The 0.18 mg FAi was recently approved in China for chronic NIU affecting the posterior segment, but real-world data in this population were lacking.

Data Highlights

Key Findings

• Significant improvement in best-corrected visual acuity (BCVA) was observed at all post-treatment time points compared to baseline (P < 0.05).
• Central macular thickness (CMT) decreased significantly from baseline through 12 months, indicating resolution of macular edema.
• Intraocular pressure (IOP) showed a mild but statistically significant increase over 12 months, remaining within manageable levels.
• Subfoveal choroidal thickness (SFCT) demonstrated a gradual decrease post-implantation, consistent with reduced inflammation.
• The cohort had a chronic, refractory disease course with prior extensive systemic and local therapies, highlighting the FAi’s efficacy in a difficult-to-treat population.
• No severe ocular or systemic adverse events were reported, supporting the implant’s favorable safety profile.

Clinical Implications

The 0.18 mg fluocinolone acetonide intravitreal implant provides sustained therapeutic benefit in patients with NIU-associated macular edema, improving visual outcomes and reducing macular thickness over 12 months. Its targeted delivery minimizes systemic exposure, offering a valuable alternative for patients with chronic, refractory disease who have previously received systemic and local corticosteroid therapies. Clinicians should monitor intraocular pressure regularly due to mild increases observed post-implantation.

Conclusion

This real-world analysis demonstrates that the 0.18 mg FAi is an effective and safe treatment option for managing macular edema secondary to non-infectious uveitis, providing sustained improvements in vision and retinal morphology over one year.

References

1. FDA Approval 2018 -- Fluocinolone Acetonide Implant for NIU
2. NMPA Approval 2022 -- 0.18 mg FAi for Chronic NIU